O'Malley Padraic G P, Sangster Shirley M, Abdelmagid Salma A, Bearne Stephen L, Too Catherine K L
Department of Biochemistry and Molecular Biology, Sir Charles Tupper Medical Building, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, Canada B3H 1X5.
Biochem J. 2005 Sep 15;390(Pt 3):665-73. doi: 10.1042/BJ20050025.
CPD-N is a cytokine-inducible CPD (carboxypeptidase-D) isoform identified in rat Nb2 T-lymphoma cells. The prototypic CPD (180 kDa) has three CP domains, whereas CPD-N (160 kDa) has an incomplete N-terminal domain I but intact domains II and III. CPD processes polypeptides in the TGN (trans-Golgi network) but the Nb2 CPD-N is nuclear. The present study identified a cryptic exon 1', downstream of exon 1 of the rat CPD gene, as an alternative transcription start site that encodes the N-terminus of CPD-N. Western-blot analysis showed exclusive synthesis of the 160 kDa CPD-N in rat Nb2 and Nb2-Sp lymphoma cells. Several haematopoietic cell lines including human K562 myeloma, Jurkat T-lymphoma and murine CTLL-2 cytotoxic T-cells express a 160 kDa CPD-immunoreactive protein, whereas mEL4 T-lymphoma cells express the 180 kDa CPD. The CPD-immunoreactive protein in hK562 cells is also nuclear and cytokine-inducible. In contrast, MCF-7 breast cancer cells express only the 180 kDa CPD, which is mainly in the TGN. CPD/CPD-N assays using substrate dansyl-L-alanyl-L-arginine show approx. 98% of CPD-N activity in the Nb2 nucleus, whereas MCF-7 CPD activity is enriched in the post-nuclear 10000 g pellet. The K(m) for CPD-N and CPD are 132+/-30 and 63+/-9 microM respectively. Specific activity/K(m) ratios show that dansyl-L-alanyl-L-arginine is a better substrate for CPD-N than for CPD. CPD-N has an optimal pH of 5.6 (due to domain II), whereas CPD has activity peaks at pH 5.6 (domain II) and pH 6.5-7.0 (domain I). CPD and CPD-N are inhibited non-competitively by zinc chelator 1,10-phenanthroline and competitively by peptidomimetic inhibitor DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid. The Nb2 CPD-N co-immunoprecipitated with phosphatase PP2A (protein phosphatase 2A) and alpha4 phosphoprotein. In summary, a cytokine-inducible CPD-N is selectively expressed in several haematopoietic tumour cells. Nuclear CPD-N is enzymatically active and interacts with known partners of CPD.
CPD-N是在大鼠Nb2 T淋巴瘤细胞中鉴定出的一种细胞因子诱导型CPD(羧肽酶D)同工型。典型的CPD(180 kDa)有三个CP结构域,而CPD-N(160 kDa)的N端结构域I不完整,但结构域II和III完整。CPD在反式高尔基体网络(TGN)中加工多肽,但Nb2 CPD-N定位于细胞核。本研究确定大鼠CPD基因外显子1下游的一个隐蔽外显子1'是一个替代转录起始位点,它编码CPD-N的N端。蛋白质免疫印迹分析显示,在大鼠Nb2和Nb2-Sp淋巴瘤细胞中特异性合成了160 kDa的CPD-N。包括人K562骨髓瘤细胞、Jurkat T淋巴瘤细胞和小鼠CTLL-2细胞毒性T细胞在内的几种造血细胞系表达一种160 kDa的CPD免疫反应性蛋白,而mEL4 T淋巴瘤细胞表达180 kDa的CPD。hK562细胞中的CPD免疫反应性蛋白也定位于细胞核且受细胞因子诱导。相比之下,MCF-7乳腺癌细胞仅表达180 kDa的CPD,主要定位于TGN。使用底物丹磺酰-L-丙氨酰-L-精氨酸进行的CPD/CPD-N分析显示,Nb2细胞核中约98%的活性为CPD-N活性,而MCF-7的CPD活性在10000 g核后沉淀中富集。CPD-N和CPD的米氏常数(K(m))分别为132±30和63±9 microM。比活性/K(m)比值表明,丹磺酰-L-丙氨酰-L-精氨酸是CPD-N比CPD更好的底物。CPD-N的最适pH为5.6(由于结构域II),而CPD在pH 5.6(结构域II)和pH 6.5 - 7.0(结构域I)有活性峰值。CPD和CPD-N受到锌螯合剂1,10-菲咯啉的非竞争性抑制以及拟肽抑制剂DL-2-巯基甲基-3-胍基乙基硫代丙酸的竞争性抑制。Nb2 CPD-N与磷酸酶PP2A(蛋白磷酸酶2A)和α4磷蛋白共免疫沉淀。总之,一种细胞因子诱导型CPD-N在几种造血肿瘤细胞中选择性表达。细胞核中的CPD-N具有酶活性,并与CPD的已知相互作用蛋白相互作用。